Full Answer
D70.8 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM D70.8 became effective on October 1, 2018. This is the American ICD-10-CM version of D70.8 - other international versions of ICD-10 D70.8 may differ.
2021 ICD-10-CM Diagnosis Code T45.1X5A Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter 2016 2017 2018 2019 2020 2021 Billable/Specific Code T45.1X5A is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
The 2019 edition of ICD-10-CM Z79.899 became effective on October 1, 2018. This is the American ICD-10-CM version of Z79.899 - other international versions of ICD-10 Z79.899 may differ.
2019 ICD-10-CM Codes 1 A00-B99 Certain infectious and parasitic diseases. 2 C00-D49 Neoplasms. 3 D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving... 4 E00-E89 Endocrine, nutritional and metabolic diseases. 5 F01-F99 Mental, Behavioral and Neurodevelopmental disorders. 6 ... (more items)
Associated ICD-10-CM Codesarsenic trioxide (Trisenox)J9017 - Injection, arsenic trioxide, 1 mg96413, 96415ixazomib (Ninlaro)J8999* - Prescription drug, oral, chemotherapeutic, not otherwise specifiedN/Alenalidomide (Revlimid)J8999* - Prescription drug, oral, chemotherapeutic, not otherwise specifiedN/A64 more rows
ICD-10-CM Code for Multiple myeloma C90. 0.
ICD-10 Codes for Long-term TherapiesCodeLong-term (current) use ofZ79.899other drug therapyH – Not Valid for Claim SubmissionZ79drug therapy21 more rows•Aug 15, 2017
ICD-10-CM Diagnosis Code Z79 Z79.
ICD-10-CM Code for Multiple myeloma and malignant plasma cell neoplasms C90.
ICD-10 code: C90. 00 Multiple myeloma Without mention of complete remission.
ICD-10 Code for Other long term (current) drug therapy- Z79. 899- Codify by AAPC. Factors influencing health status and contact with health services. Persons with potential health hazards related to family and personal history and certain conditions influencing health status.
Other specified abnormal findings of blood chemistryICD-10 code R79. 89 for Other specified abnormal findings of blood chemistry is a medical classification as listed by WHO under the range - Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified .
Z79. 899 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM Z79. 899 became effective on October 1, 2021.
ICD-10 code Z51. 81 for Encounter for therapeutic drug level monitoring is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Z51. 81 Encounter for therapeutic drug level monitoring - ICD-10-CM Diagnosis Codes.
You also may want to use additional codes as appropriate, such as Z79. 01 (Long term (current) use of anticoagulants) if the patient is taking anticoagulants, Z51. 81 (Encounter for therapeutic drug level monitoring) if the agency is monitoring PT/INRs, and Z95.
The 2022 edition of ICD-10-CM Z79.899 became effective on October 1, 2021.
Z77-Z99 Persons with potential health hazards related to family and personal history and certain conditions influencing health status
Long term current use of leflunomide (arava) Long term current use of lenalidomide (revlimid) Long term current use of lithium. Long term current use of medication for add and or adhd. Long term current use of medication for attention deficit disorder (add) or attention deficit hyperactivity disorder (adhd)
The 2022 edition of ICD-10-CM T45.1X5A became effective on October 1, 2021.
Use secondary code (s) from Chapter 20, External causes of morbidity, to indicate cause of injury. Codes within the T section that include the external cause do not require an additional external cause code. Type 1 Excludes.
T45- Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified
The 2022 edition of ICD-10-CM D70.8 became effective on October 1, 2021.
D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism